Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Donaperminogene Seltoplasmid
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1/2a Trial of Gene Therapy Engensis for CMT1A Begins in Korea
Details : The trial aims to evaluate Engensis’ safety and tolerability by administering the treatment to the leg of twelve CMT1A patients in Korea.
Product Name : Engensis
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Donaperminogene Seltoplasmid
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable